These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 37737688)

  • 41. PD-1 blockade synergizes with intratumoral vaccination of a therapeutic HPV protein vaccine and elicits regression of tumor in a preclinical model.
    Peng S; Tan M; Li YD; Cheng MA; Farmer E; Ferrall L; Gaillard S; Roden RBS; Hung CF; Wu TC
    Cancer Immunol Immunother; 2021 Apr; 70(4):1049-1062. PubMed ID: 33108473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model.
    Durgan K; Ali M; Warner P; Latchman YE
    Cancer Immunol Immunother; 2011 Apr; 60(4):547-58. PubMed ID: 21240487
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-PD-1/anti-CTLA-4 efficacy in melanoma brain metastases depends on extracranial disease and augmentation of CD8
    Taggart D; Andreou T; Scott KJ; Williams J; Rippaus N; Brownlie RJ; Ilett EJ; Salmond RJ; Melcher A; Lorger M
    Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1540-E1549. PubMed ID: 29386395
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.
    Salmon H; Idoyaga J; Rahman A; Leboeuf M; Remark R; Jordan S; Casanova-Acebes M; Khudoynazarova M; Agudo J; Tung N; Chakarov S; Rivera C; Hogstad B; Bosenberg M; Hashimoto D; Gnjatic S; Bhardwaj N; Palucka AK; Brown BD; Brody J; Ginhoux F; Merad M
    Immunity; 2016 Apr; 44(4):924-38. PubMed ID: 27096321
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tumor Endothelial Cell-Mediated Antigen-Specific T-cell Suppression via the PD-1/PD-L1 Pathway.
    Taguchi K; Onoe T; Yoshida T; Yamashita Y; Tanaka Y; Ohdan H
    Mol Cancer Res; 2020 Sep; 18(9):1427-1440. PubMed ID: 32527950
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Combination of PD-1 Checkpoint Blockade and Botulinum Toxin Type A1 Improves Antitumor Responses in Mouse Tumor Models of Melanoma and Colon Carcinoma.
    Kwak S; Lee JY; Kim MJ; Lee HJ; Lee DK; Kang J; Kang WH; Son WC; Cruz DJM
    Immunol Invest; 2023 Nov; 52(6):749-766. PubMed ID: 37403798
    [TBL] [Abstract][Full Text] [Related]  

  • 47. siRNA silencing of PD-1 ligands on dendritic cell vaccines boosts the expansion of minor histocompatibility antigen-specific CD8(+) T cells in NOD/SCID/IL2Rg(null) mice.
    van der Waart AB; Fredrix H; van der Voort R; Schaap N; Hobo W; Dolstra H
    Cancer Immunol Immunother; 2015 May; 64(5):645-54. PubMed ID: 25724840
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HIV gag protein is efficiently cross-presented when targeted with an antibody towards the DEC-205 receptor in Flt3 ligand-mobilized murine DC.
    Bozzacco L; Trumpfheller C; Huang Y; Longhi MP; Shimeliovich I; Schauer JD; Park CG; Steinman RM
    Eur J Immunol; 2010 Jan; 40(1):36-46. PubMed ID: 19830741
    [TBL] [Abstract][Full Text] [Related]  

  • 49. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
    Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
    Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma.
    Bellone M; Cantarella D; Castiglioni P; Crosti MC; Ronchetti A; Moro M; Garancini MP; Casorati G; Dellabona P
    J Immunol; 2000 Sep; 165(5):2651-6. PubMed ID: 10946294
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Anti-CTLA-4 antibody-functionalized dendritic cell-derived exosomes targeting tumor-draining lymph nodes for effective induction of antitumor T-cell responses.
    Phung CD; Pham TT; Nguyen HT; Nguyen TT; Ou W; Jeong JH; Choi HG; Ku SK; Yong CS; Kim JO
    Acta Biomater; 2020 Oct; 115():371-382. PubMed ID: 32798721
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined alpha tumor necrosis factor gene therapy and engineered dendritic cell vaccine in combating well-established tumors.
    Liu Y; Saxena A; Zheng C; Carlsen S; Xiang J
    J Gene Med; 2004 Aug; 6(8):857-68. PubMed ID: 15293344
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Case Report:
    Huang JW; Kuo CL; Wang LT; Ma KS; Huang WY; Liu FC; Yang KD; Yang BH
    Front Immunol; 2021; 12():752563. PubMed ID: 35003064
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A novel T cell-based vaccine capable of stimulating long-term functional CTL memory against B16 melanoma via CD40L signaling.
    Xie Y; Wang L; Freywald A; Qureshi M; Chen Y; Xiang J
    Cell Mol Immunol; 2013 Jan; 10(1):72-7. PubMed ID: 23042534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
    Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
    Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.
    Shi W; Yang X; Xie S; Zhong D; Lin X; Ding Z; Duan S; Mo F; Liu A; Yin S; Jiang X; Xu ZPG; Lu X
    Cancer Lett; 2021 Dec; 522():184-197. PubMed ID: 34562519
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Synergistic anti-tumor efficacy of a hollow mesoporous silica-based cancer vaccine and an immune checkpoint inhibitor at the local site.
    Wang X; Li X; Ito A; Sogo Y; Ohno T
    Acta Biomater; 2022 Jun; 145():235-245. PubMed ID: 35398544
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Anticancer effects of chemokine-directed antigen delivery to a cross-presenting dendritic cell subset with immune checkpoint blockade.
    Mizumoto Y; Hemmi H; Katsuda M; Miyazawa M; Kitahata Y; Miyamoto A; Nakamori M; Ojima T; Matsuda K; Nakamura M; Hayata K; Fukuda-Ohta Y; Sugiyama M; Ohta T; Orimo T; Okura S; Sasaki I; Tamada K; Yamaue H; Kaisho T
    Br J Cancer; 2020 Apr; 122(8):1185-1193. PubMed ID: 32066911
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Dendritic cells loaded with stressed tumor cells elicit long-lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells.
    Prasad SJ; Farrand KJ; Matthews SA; Chang JH; McHugh RS; Ronchese F
    J Immunol; 2005 Jan; 174(1):90-8. PubMed ID: 15611231
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
    Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
    J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.